Axa S.A. Supernus Pharmaceuticals, Inc. Transaction History

Axa S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$24.15 - $31.45 $214,935 - $279,905	-8,900 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$17.7 - $25.81 $157,530 - $229,709	8,900 New	8,900 $224,000
Q4 2019 Feb 18, 2020	SELL	$19.93 - $29.13 $3.76 Million - $5.49 Million	-188,446 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $172,355 - $225,814	-6,767 Reduced 3.47%	188,446 $5.18 Million
Q2 2019 Aug 13, 2019	BUY	$29.96 - $38.87 $444,456 - $576,636	14,835 Added 8.22%	195,213 $6.46 Million
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $1.02 Million - $1.31 Million	31,255 Added 20.96%	180,378 $6.32 Million
Q4 2018 Feb 13, 2019	BUY	$30.84 - $49.51 $697,107 - $1.12 Million	22,604 Added 17.87%	149,123 $4.95 Million
Q3 2018 Nov 08, 2018	BUY	$42.7 - $56.55 $5,294 - $7,012	124 Added 0.1%	126,519 $6.37 Million
Q2 2018 Aug 13, 2018	SELL	$44.1 - $59.85 $2.65 Million - $3.59 Million	-60,056 Reduced 32.21%	126,395 $7.57 Million
Q1 2018 May 14, 2018	SELL	$37.15 - $46.9 $96,478 - $121,799	-2,597 Reduced 1.37%	186,451 $8.54 Million
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $6.95 Million - $9.39 Million	189,048	189,048 $7.56 Million

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.96B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.